In-vivo Bioequivalence Test of Dasatinib tablets with brand drug (SPRYCEL® 140 mg, Rosche, Switzerlandd)
Not Applicable
Recruiting
- Conditions
- Plasma drug concentration.
- Registration Number
- IRCT20200105046010N56
- Lead Sponsor
- anoalvand Pharmaceutical Co
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General health
Body mass index between18-28
Informed consent
Informed consentBeing at the age of 18-60 years old
Exclusion Criteria
Smoking
A history of cardiovascular disease
A history of liver & kidney disease
Pregnancy
Alcohol & Drug addiction
Hypersensitivity to the drug
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma drug concentration. Timepoint: Sampling times in this study will be 0, 0:30, 1, 1:30, 2, 2:20, 3, 3:5, 4, 4:30, 5, 6, 8, 10, 24, 48, 72 hours after prescribing the tablet. Method of measurement: High Performance Liquid Chromatography with tandem mass spectroscopy detector.
- Secondary Outcome Measures
Name Time Method